John S. Shaw - Concepedia

Concepedia

Author

John S. Shaw

AstraZeneca (United Kingdom)ORCID

Also Known As

J S Shaw, J Shaw, J. S. SHAW, J. S. Shaw, J. Shaw, J.S Shaw, J.S. Shaw, John S Shaw, John S. Shaw, John Shaw

42

Publications

2.7K

Citations

21

H-Index

68

Concepts

All Affiliations

AstraZeneca (United Kingdom)East Cheshire NHS Trust St Thomas' Hospital Loughborough University Imperial College London

JS

About

John S. Shaw is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and molecular pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	2.2K
2	Natural Sciences	6	6	231
3	Health Sciences	3	3	183
4	Social Sciences	3	3	1.5K
5	Engineering	2	2	145

John S. Shaw

×

27

Publications

2.7K

Citations

21

H-Index

	Year	Citations
(–)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor Norman G. Bowery, David R. Hill, Alan L. Hudson, Nature Molecular PharmacologyNeurophysiologyMedicineSynaptic TransmissionNeurotransmitter	1980	1.1K
Bicuculline-insensitive gaba receptors on peripheral autonomic nerve terminals Norman G. Bowery, Adam Doble, David R. Hill, European Journal of Pharmacology NeurophysiologyBicuculline-insensitive Gaba ReceptorsPhysiologyNeuropharmacologyNeurotransmission	1981	376
Sequence Selective Polymerization Catalysis: A New Route to ABA Block Copoly(ester-<i>b</i>-carbonate-<i>b</i>-ester) Shyeni Paul, Charles Romain, John S. Shaw, Macromolecules Carbon DioxideMacromolecular ChemistryEngineeringRing-opening PolymerizationChemistry	2015	131
A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium Frank Lally, Emily Smith, Andrew Filer, Arthritis & Rheumatism	2005	126
The contribution of intrinsic activity to the action of opioids <i>in vitro</i> Lynne Miller, John S. Shaw, Elaine Whiting British Journal of Pharmacology	1986	94
2-(3,4-Dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted-ethyl]-acetamides: the use of conformational analysis in the development of a novel series of potent opioid .kappa. agonists Gerard Costello, Roger James, John S. Shaw, Journal of Medicinal Chemistry Combinatorial ChemistryOrganic ChemistryPharmacotherapyHeterocycle ChemistryExperimental Pharmacology	1991	75
ICI 204448: a κP‐opioid agonist with limited access to the CNS John S. Shaw, Jacqueline A. Carroll, Pete Alcock, British Journal of Pharmacology Opioid EpidemicPain MedicineMolecular PainPharmacotherapyExperimental Pharmacology	1989	74
A novel series of potent and selective agonists at the opioid κ-receptor Gerard Costello, Brain G. Main, Jeffrey J. Barlow, European Journal of Pharmacology Molecular PharmacologyNovel SeriesOpioid κ-ReceptorMedicineDrug Discovery	1988	70
Duffy antigen receptor for chemokines and CXCL5 are essential for the recruitment of neutrophils in a multicellular model of rheumatoid arthritis synovium Emily Smith, Helen M. McGettrick, Michael Stone, Arthritis & Rheumatism	2008	62
Differential sensitivity of antinociceptive assays to the bradykinin antagonist Hoe 140 Christopher G. Heapy, John S. Shaw, Susannah C. Farmer British Journal of Pharmacology Pain MedicineImmunologyNeuropathic PainMolecular PainPharmacotherapy	1993	59

Page 1